Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Obesity
Interventions
DRUG

NO-13065

"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."

DRUG

Placebo

Two subjects per cohort will take a matched placebo.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Otsuka Pharmaceutical Factory, Inc.

INDUSTRY